Latest Articles
Ane Gerda Zahl Eriksson: SENSOR-LIIFE - Advancing Exercise Research in Endometrial Cancer Survivor - Oncodaily
Ane Gerda Zahl Eriksson: SENSOR-LIIFE - Advancing Exercise Research in Endometrial Cancer Survivor Oncodaily
Published: Nov. 16, 2025, 9:57 a.m.
Endometrial Cancer Cure Rate: What Patients Need to Know in 2025 - Oncodaily
Endometrial Cancer Cure Rate: What Patients Need to Know in 2025 Oncodaily
Published: Nov. 16, 2025, 8:17 a.m.
Circulating miRNA as diagnostic tools for gynecological diseases and their applications in biosensor development.
MicroRNAs (miRNAs) have emerged as robust biomarkers for diagnosing and prognosing gynecological diseases due to their disease-specific expression and remarkable stability in body fluids. Despite the inherent instability of RNA …
Published: Nov. 15, 2025, midnight
FDA approves Promega’s OncoMate test to guide personalised treatment for endometrial cancer - Indian Pharma Post
FDA approves Promega’s OncoMate test to guide personalised treatment for endometrial cancer Indian Pharma Post
Published: Nov. 14, 2025, 3:26 p.m.
Metabolomics reveals the therapeutic efficacy of liposomal resvida in endometrial cancer through regulating autophagy-related gene expression - Cancer Cell International
Metabolomics reveals the therapeutic efficacy of liposomal resvida in endometrial cancer through regulating autophagy-related gene expression Cancer Cell International
Published: Nov. 14, 2025, 4:25 a.m.
Acrivon Therapeutics Advances ACR-368 in Phase 2b Trial for Endometrial Cancer and Prepares for Initial Data on ACR-2316 - Quiver Quantitative
Acrivon Therapeutics Advances ACR-368 in Phase 2b Trial for Endometrial Cancer and Prepares for Initial Data on ACR-2316 Quiver Quantitative
Published: Nov. 13, 2025, 9:25 p.m.
FDA Approves Promega OncoMate® MSI Dx as Companion Diagnostic for KEYTRUDA® and LENVIMA® in Endometrial Cancer - Voice Of HealthCare
FDA Approves Promega OncoMate® MSI Dx as Companion Diagnostic for KEYTRUDA® and LENVIMA® in Endometrial Cancer Voice Of HealthCare
Published: Nov. 13, 2025, 6:17 a.m.
FDA Approves Diagnostic Tool for Pembrolizumab Combo in Endometrial Cancer - CancerNetwork
FDA Approves Diagnostic Tool for Pembrolizumab Combo in Endometrial Cancer CancerNetwork
Published: Nov. 12, 2025, 7:12 p.m.
Sylvester Comprehensive Cancer Center Launches Clinical Trial on Fasting for Endometrial Cancer - University of Miami
Sylvester Comprehensive Cancer Center Launches Clinical Trial on Fasting for Endometrial Cancer University of Miami
Published: Nov. 12, 2025, 1:59 p.m.
Mathematical model of optimal control for endometrial cancer with treatments dostarlimab and chemotherapy using Caputo derivative - Nature
Mathematical model of optimal control for endometrial cancer with treatments dostarlimab and chemotherapy using Caputo derivative Nature
Published: Nov. 11, 2025, 8:42 p.m.
Link copied to clipboard!